STL Volume 31 Number 4

Most molluscum contagiosum lesions resolve on their own, but symptomatic or cosmetically troubling cases have long been managed with off-label agents and destructive procedures. That changed with the FDA approval of cantharidin 0.7% drug-device applicator in 2023 and berdazimer 10.3% gel in 2024. This review examines the trial evidence behind both, compares them with potassium hydroxide, salicylic acid, cryotherapy, curettage, and pulsed dye laser, and addresses the treatment gaps that remain in immunocompromised patients and those with atopic dermatitis.

The skin has long been read as a mirror of internal disease, but its relationship with bone is less familiar. Dermis and bone share a common embryonic origin, overlapping cell lineages, and collagen as a structural backbone. This review examines the skin-bone axis — vitamin D signalling, cystatin A, inflammatory dermatoses, corticosteroid effects on bone, cutaneous signs of metabolic and autoinflammatory bone disease, and the gut microbiome's role in both — and makes the case for a multidisciplinary approach to healthy aging.

Update on Dupilumab for SC injection (Dupixent®) and Adapalene 0.1% + benzoyl peroxide 2.5% acne treatment (Differin® Epiduo® Acne Gel). Also, in June 2026, bemotrizinol – long used internationally as Tinosorb® S – has become the first new FDA‑approved sunscreen filter in over 20 years.